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Key message 
This phase IB study established a dose and schedule of vistusertib (dual m-TORC1/2 
inhibitor) in combination with weekly paclitaxel. Response rates in pre-treated populations of 
patients in the expansion cohorts of HGSOC and squamous NSCLC were 52% and 35%, 
respectively.  Progression-free survival in both cohorts was 5.8 months. Randomised trials of 
this combination are warranted. 
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Abstract 
Background  
We have previously shown that raised p-S6K levels correlate with resistance to 
chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the 
dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in 
such patients.  
Patients and Methods 
In dose escalation, weekly paclitaxel (80 mg/m2) was given 6/7 weeks in combination with 
two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule 
A, vistusertib dosed bd for 3 consecutive days per week (3/7days) and schedule B, 
vistusertib dosed bd for 2 consecutive days per week (2/7days). After establishing a 
recommended phase II dose (RP2D), expansion cohorts in high-grade serous ovarian 
cancer (HGSOC) and squamous non-small cell lung cancer (sqNSCLC) were explored in 25 
and 40 patients, respectively. 
Results 
The dose escalation arms comprised 22 patients with advanced solid tumours. The dose-
limiting toxicities were fatigue and mucositis in schedule A and rash in schedule B. Based on 
toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) evaluations, the RP2D was 
established as 80 mg/m2 paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks. In the 
HGSOC expansion RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 
(64%), respectively with median progression-free survival (mPFS) of 5.8 months (95% CI: 
3.28 - 18.54). The RP2D was not well tolerated in the SqNSCLC expansion, but toxicities 
were manageable after the daily vistusertib dose was reduced to 25 mg bd for the following 
23 patients. The RECIST response rate in this group was 8/23 (35%) and the mPFS was 5.8 
months (95% CI: 2.76 - 21.25). 
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Discussion 
In this phase I trial we report a highly active and well tolerated combination of vistusertib, 
administered as an intermittent schedule with weekly paclitaxel, in patients with HGSOC and 
SqNSCLC.  
Clinical trial registration: ClinicialTrials.gov identifier: CNCT02193633 
Key words: Phase 1; m-TORC1/m-TORC2 inhibitor; combination therapy; ovarian cancer; 
squamous non-small cell lung cancer 
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Introduction  
We have previously studied cancer cells isolated from serous effusions and shown raised p-
S6K to be associated with chemo-resistance and poor clinical outcome in ovarian and lung 
cancers, respectively [1, 2]. This led us to hypothesise that inhibition of m-TOR signalling, in 
combination with chemotherapy, could improve treatment outcomes in these tumour types. 
Analogues of rapamycin such as everolimus have been recognised to inhibit only m-TORC1 
and not m-TORC2 in the m-TOR complex [3]. The dual m-TORC1/2 inhibitor vistusertib 
(AZD2014) has a short half-life, giving greater flexibility for intermittent dosing schedules [4, 
5]. Weekly paclitaxel was chosen as the chemotherapy backbone as it is often used to treat 
advanced ovarian cancer. Pre-clinical studies of vistusertib and paclitaxel revealed an 
additive effect on growth in vitro and in vivo, with the combination showing increased 
apoptosis and metabolic effects consistent with the mechanism of action of vistusertib [6].  
 
Here, we report the results of the TAX-TORC study, a phase Ib dose-escalation study, with a 
pre-planned dose-expansion cohort in HGSOC and an additional expansion cohort in 
sqNSCLC (supplementary Figure S1).  
 
Methods - Patients  
Conduct of the study 
The academic sponsors of this study were The Institute of Cancer Research and The Royal 
Marsden (CCR3667) and the trial was reviewed by a central research ethics committee 
(REC ref: 13/LO/0066). The study was funded by AstraZeneca. Nine Experimental Cancer 
Medicine Centres across the UK participated in this study. All patients were treated after 
obtaining written, informed consent. Cancer Research UK trial number: CRUKD/12/013.  
 
Inclusion/exclusion criteria: Inclusion criteria in the dose escalation arm included an ECOG 
performance status of 0 or 1. Haematological and biochemistry criteria were standard for 
phase I studies and details are available in the supplementary data.     
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Treatment 
80 mg/m2 paclitaxel was administered once weekly for 6/7 weeks in a 7-week cycle. In the 
first week of the dose escalation cohorts, patients received only paclitaxel on C1D1, then 
vistusertib on C1D3 to allow for PK and PD sampling.  Patients then received weekly 
paclitaxel (on days 8, 15, 22, 29, 36) with vistusertib, also starting on days 8, 15, 22, 29, 36, 
given orally twice daily either for three consecutive days per week (schedule A: 3/7days, 6/7 
weeks) or two consecutive days per week (schedule B: 2/7days, 6/7 weeks).  In the dose 
expansion, schedule A was taken forward with patients dosing with vistusertib weekly on 
days 1 - 3 for 6 weeks of a 7-week cycle. 
 
Evaluation of toxicity 
NCI-CTCAE V4·0 was used to assess toxicity.  
 
Evaluation of response 
RECIST v1.1 was used to assess tumour response supported by GCIG CA125 response in 
HGSOC patients. Response was assessed at the end of every 7-week cycle. 
 
Methods – Materials and methods 
Pharmacokinetic and pharmacodynamic evaluation 
PK sampling was carried out for all patients in the dose escalation arm for 24 hours on C1D1 
(paclitaxel alone), C1D3 (vistusertib alone), and on C1D1 (combination of paclitaxel and 
vistusertib). PD sampling was carried out for all patients in the dose escalation arm.  
Sampling for PD assays was carried out on the same days as PK sampling. Phosphorylation 
of AKTSer473 (Ser473 p-AKT) was quantified in platelet-rich plasma (PRP) (for detailed 
methods see supplementary data) [7].  
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Sequencing 
DNA was extracted from formalin-fixed and paraffin-embedded (FFPE) tumour blocks. In 
addition, circulating free DNA (cfDNA) when collected at baseline, at the end of cycle 1 and, 
where possible, at progression, was extracted from 4 - 8 mL of plasma. Sequencing libraries 
were constructed using a customised Generead DNAseq Mix-n-Match v2 panel (Qiagen) 
covering 4841 amplicons (310,077 bp) across 67 genes. Libraries were run using the MiSeq 
Sequencer (Illumina), sequence alignment and mutation calling were performed.   
 
Methods – Statistical analysis 
The data cut-off for this paper was 01 October 2017. Demographics were analysed by 
descriptive statistics. Safety was assessed in all enrolled patients. Patients considered not 
assessable for response had no post-baseline CT scan. The number of patients required for 
the dose escalation phase was dependent on toxicities observed as the trial progressed. No 
formal power calculations were done.  
 
Progression-free survival was estimated by the Kaplan-Meier method, beginning on the day 
of the first dose (C1D1) and continuing until disease progression.  Patients who came off 
study for reasons other than disease progression (clinical or RECIST) were censored.  This 
study is registered with ClinicalTrials.gov, identifier: NCT02193633. 
 
Results 
Dose escalation cohort 
Toxicity 
Twenty-two patients were recruited to the dose escalation cohort.  The most common 
tumours were ovarian and lung cancer (supplementary Table S1).  In the dose escalation 
phase, vistusertib was tested at 25 mg, 50 mg and 75 mg bd 3/7days, 6/7 weeks (schedule 
A) with no dose limiting toxicities (DLTs) in the 25 mg or 50 mg groups.  Two of the three 
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patients in the 75 mg group experienced DLTs of fatigue and mucositis.  Vistusertib was 
then tested at 50 mg and 75 mg bd 2/7 days (schedule B) with no DLTs. However, two of the 
three patients taking 100 mg bd 2/7 days experienced DLTs of rash (supplementary Figure 
S2).  The maximally tolerated dose (MTD) of schedule A was thus 80 mg/m2 weekly 
paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks in a 7-week cycle, with dosing 
starting concurrently on day 1 of each week. The MTD of schedule B was 80 mg/m2 weekly 
paclitaxel with 75 mg vistusertib bd 2/7 days for 6/7 weeks in a 7-week cycle, with dosing 
starting concurrently on day 1 of each week. The most common toxicities across both 
schedules were predominantly grade 1 - 2 fatigue, nausea, anaemia, and diarrhoea (Table 
1), which are similar to that seen with weekly paclitaxel administration. 
 
Pharmacokinetics 
In all schedules tested, the PK of paclitaxel when administered alone or in combination with 
vistusertib was similar (Table 2). The PK of vistusertib alone or vistusertib in combination 
with paclitaxel in both schedules was comparable with previous single agent studies [5] (data 
not shown). The areas under the curve (AUC) versus dose of vistusertib was approximately 
dose proportional (supplementary Figure S3). Altogether, these suggest that there is no 
drug-drug PK interaction on drug exposure for either paclitaxel or vistusertib in combination 
compared with either agent administered alone. 
 
Pharmacodynamics 
At the recommended phase II dose level of 50 mg bd of vistusertib and 80 mg/m2 of 
paclitaxel, there was a statistically non-significant increase in levels of Ser473 p-AKT 4 hours 
following 80 mg/m2 paclitaxel (1.4 fold; P = 0.14).  Vistusertib (50 mg bd 3/7) in addition to 
paclitaxel produced a reduction in Ser473 p-AKT at 4 hours post-vistusertib to 53% of pre-
dose levels (P = 0.0495). This was 62% lower than the corresponding time-point following 
paclitaxel alone, suggesting that at the RP2D of the combination, there is a significant 
reduction in p-AKT levels in normal tissue compared to baseline (Figure 1).  
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Recommended phase II dose 
In combination with weekly paclitaxel administered at 80 mg/m2 once weekly, the MTD of 
vistusertib was 50 mg bd (3/7days) (schedule A) or 75 mg bd (2/7days) (schedule B).  Both 
doses had acceptable PK and PD profiles and would be acceptable as per the 
pharmacological audit trail [8].  Weekly vistusertib 50 mg bd 3 days on/4 days off combined 
with weekly paclitaxel 80 mg/m2 was taken forward as the RP2D based on reduced 
occurrence of grade 3 fatigue in this cohort. 
 
Ovarian cancer expansion  
Twenty-seven patients with relapsed/refractory HGSOC were treated at the recommended 
phase II dose.  Two patients were replaced as per protocol and were not considered for 
assessment of response. The median number of previous treatments was three: the majority 
(26/27; 96%) of patients having received paclitaxel and 3/27 patients (11%) having 
previously received weekly paclitaxel (supplementary Table S2). The RECIST and CA125 
response rates were 13/25 (52%) and 16/25 (64%), respectively (Figure 2A). The mPFS was 
5·8 months (95% CI: 3.3 - 18.5).  
 
DNA sequencing (targeted panel of 67 genes) of FFPE tissue revealed the most common 
mutation was TP53 detected in 23/25 (92%) patients. There was no correlation between 
specific mutations and response (Figure 2B). 
 
Squamous lung cancer expansion  
Following two partial responses in patients with sqNSCLC in the dose escalation cohort, we 
conducted a dose expansion in a cohort of 40 patients, starting at the RP2D of 80 mg/m2 
paclitaxel and 50 mg vistusertib bd 3/7 days. This schedule was poorly tolerated with fatigue, 
diarrhoea and pneumonia being seen more frequently than in the dose escalation cohort 
(supplementary Table S3A). The safety review committee reviewed the data of the first 17 
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patients and decided to reduce the dose of vistusertib to 25 mg bd 3/7 days for the 
remaining 23 patients due to be treated in this cohort. This dose was known to be 
pharmacodynamically active [5] and was better tolerated (supplementary Table S3B). The 
RECIST response rate in patients with sqNSCLC in the 25 mg cohort was 8/23 (35%) 
(Figure 3A), with an mPFS of 5.8 months (95% CI 2.8-21.3).  Two patients with PIK3CA 
mutations had partial responses but there were no clear patterns linking mutations to 
response (Figure 3B). 
 
Discussion  
We report the first study of the combination of weekly paclitaxel with the dual m-TORC1/2 
inhibitor, vistusertib, establishing a safe dose and schedule and preliminary evidence of 
efficacy in HGSOC and SqNSCLC. We chose to investigate the m-TORC1/2 inhibitor in the 
context of weekly paclitaxel as this regimen is often used in the setting of platinum-resistant 
ovarian cancer [9] and taxanes are commonly used in the treatment of platinum-resistant 
NSCLC (with comparable efficacy between weekly paclitaxel and docetaxel and better 
tolerability profile) [10, 11].  
 
Toxicities of fatigue, nausea, anaemia and diarrhoea in this dose escalation cohort were not 
dissimilar to previous studies combining m-TOR inhibitors such as everolimus [12], 
ridaforolimus [13] or the m-TORC1/2 inhibitor, MLN028 [14], with weekly paclitaxel regimens.  
Hyperglycaemia, which has been commonly reported with m-TOR inhibitors, occurred at a 
very low incidence in our study (all grades: N = 8 (11%), grade 3/4: N = 1(1%)).  It was noted 
that many previous studies were in breast cancer where weekly paclitaxel is often used as 
standard-of-care. Of interest, in our study patients with heavily pre-treated HGSOC tolerated 
vistusertib at 50 mg bd 3 days per week in combination with weekly paclitaxel. However, 
patients with sqNSCLC needed a dose reduction of vistusertib to 25 mg bd 3 days per week.  
Patients with sqNSCLC often have risk factors and co-morbidities that correlate with poor 
tolerance of chemotherapy such as hypoxia, a history of smoking and pulmonary fibrosis 
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[15].  We have previously reported on the increased risk of infections of patients treated with 
PI3K pathway inhibitors used as part of combination therapy [16].  In our experience, this is 
the first time that it has been necessary to recommend two separate doses for different 
tumour types within the same study.  
 
The pharmacokinetic profile of vistusertib was not significantly different from previous reports 
in single agent studies [5], and was no different when administered alone or in combination 
with paclitaxel. The pharmacodynamic profile of vistusertib in PRP showed administration of 
vistusertib led to abrogation of AKTSer473 phosphorylation, providing proof-of-principle of 
the desired biological effect of inhibiting the PI3K–Akt-m-TOR pathway.   
 
The clinical outcomes of patients receiving the combination of weekly paclitaxel and 
vistusertib in this non-randomised phase I expansion were encouraging for the patient 
groups explored. In the ovarian cohort the median lines of previous treatment were three: 
12% of patients were platinum-refractory, 48% had progressed within 6 months of the last 
platinum treatment, and 96% had progressed within a year of their last platinum treatment.  
In this cohort the RECIST and CA125 response rate was 52% and 64%, respectively, with a 
progression-free interval of 5.8 months, which is better than historic data reported for the use 
of weekly paclitaxel therapy [9]. The control chemotherapy arm of a contemporary phase III 
study studying the addition of bevacizumab to chemotherapy in the setting of 2nd or 3rd line 
chemotherapy in a platinum-resistant disease state achieved a response rate of 12% and 
progression-free survival was 3.9 months [17]. The results of the TAX-TORC study have led 
to a randomised phase II study of weekly paclitaxel versus paclitaxel and vistusertib, which 
is ongoing (ISRCTN16426935) [18]. 
 
The standard-of-care of sqNSCLC changed with the introduction of immune checkpoint 
inhibitors with response rates of ~15% in patient cohorts not selected for PD-L1 expression  
confirmed by randomised control trials [19]. In the TAX-TORC study, at the tolerated doses 
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of paclitaxel (80 mg/m2/week) and vistusertib (25 mg bd 3/7 days), the response rate and 
progression-free survival was 35% and 5.8 months, respectively. These data exceed 
traditional outcomes for the sqNSCLC population beyond first-line therapy and demonstrate 
potential for benefit and warrant further evaluation.  A possible use of this regimen could be 
in the setting of patients with sqNSCLC who do not have expression of PD-L1 [20]. 
 
We attempted to identify biomarkers of response to the combination by studying a panel of 
67 genes that were known to be commonly mutated in HGSOC [21] and sqNSCLC [22]. The 
mutations found in our study were in keeping with those described elsewhere in these 
tumour types; however, there were no significant differences in mutation profiles of 
responders and non-responders in this small dataset.  
 
Conclusion 
We report a phase I study combining weekly paclitaxel and a dual m-TORC1/2 inhibitor, 
vistusertib, with expansions in high-grade serous ovarian cancer and squamous non-small 
cell lung cancer, which are both areas of unmet need.  The trial showed tolerable schedules 
in expansion cohorts of over 20 patients. The response rates and progression-free survival 
in these non-randomised phase I expansions show promise and randomised phase II 
studies are recommended to study these combinations further. 
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Table legends 
 
Table 1. Toxicity in the dose escalation arm 
All drug related events (possibly, probably and, definitely related) seen in more than 20% of 
patients in the dose escalation cohorts. A total of 22 patients were treated in the dose escalation.  
One patient was treated with vistusertib on schedule B at 50 mg instead of 100 mg due to urgent 
reporting of two dose-limiting toxicities.  The patient did not have grade 3 or 4 toxicity or a DLT, 
was evaluable, but has not been represented in the table for simplicity. 
 
Table 2.  Pharmacokinetic profile of vistusertib 
The area under the curve (AUC), maximal concentration (Cmax) and half-life (HL) of vistusertib 
on C1D3 (administered as a single agent) and C1D8 (administered in combination with paclitaxel) 
across the different dose levels in the dose escalation cohort. 
 
 
 
Figure legends 
 
Figure 1 
Pharmacodynamic profile of vistusertib at 50 mg bd 3/7 
Phosphorylation of AKT (Ser473) in platelet-rich plasma was quantified using MSD 
electrochemiluminescent immunoassays and normalised to corresponding total AKT values. 
Baseline values were established prior to the start of treatment. On C1D1 only paclitaxel (80 
mg/m2) was administered and a non-significant rise in p-ATK at 4 hours following treatment was 
noted. On C1D4 a single dose of vistusertib was administered and non-significant reduction of p-
AKT was seen. On C1D8 the combination of paclitaxel and vistusertib was administered, which 
caused a significant reduction of p-AKT compared to baseline. Points represent individual 
patients, orange line represents mean of up to N = 6 patients. Four samples were excluded 
because of haemolysis which interfered with the assay (*P<0.05; paired t test).  
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Figure 2 
Clinical outcomes of patients in the ovarian cancer expansion treated at the R2PD for ovarian 
cancer 
A) Waterfall plot of 23/25 patients with ovarian cancer treated at the RP2D for ovarian cancer that 
were evaluable for response; two patients clinically progressed with bowel obstruction in the first 
cycle and did not have a repeat CT scan to assess response. Nineteen of 25 (76%) patients 
showed a reduction in size of their tumour, with 13/25 (52%) achieving a partial response. B) 
Mutations in tumour tissue or plasma of patients compared with clinical response. C) Spider plots 
representing percentage change in measured sum of tumour dimensions of individual patients 
over time (each cycle is 7 weeks).  
 
Figure 3 
Clinical outcomes of patients in the squamous NSCLC expansion treated at the R2PD for 
squamous NSCLC 
A) Waterfall plot of 21/23 patients with sqNSCLC treated at RP2D of the combination; two 
patients clinically progressed within their first cycle and repeat radiological evaluation was not 
done. Eighteen of the 23 (78%) patients showed reduction in the size of their tumour with 8/23 
(35%) achieving a partial response. B) Mutations in tumour tissue or plasma of patients 
compared with clinical response. C) Spider plots representing percentage change in measured 
sum of tumour dimensions of individual patients over the time (each cycle is 7 weeks).  
 
 
 
1 
 
Adverse Event 
Escalation 3d on, 4d off Escalation 2d on, 5d off 
Total 
(N=21) 
25 mg (N=3) 50 mg (N=6) 75 mg (N=3) 75 mg (N=6) 100 mg (N=3) 
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4 
Fatigue 3 0 5 0 0 3 1 2 1 1 16 
Nausea 3 0 4 0 0 0 4 0 2 0 13 
Anaemia 2 0 4 0 2 0 2 0 2 0 12 
Diarrhoea 1 0 3 1 1 1 3 0 1 0 11 
Peripheral sensory 
neuropathy 1 0 2 0 1 0 3 0 2 0 9 
Skin rash 1 0 1 0 1 0 3 0 1 2 9 
Alopecia 1 0 4 0 2 0 1 0 0 0 8 
Dysgeusia 0 0 3 0 1 0 4 0 0 0 8 
Mucositis 1 0 2 0 1 1 1 0 1 0 7 
Neutropenia 0 0 2 1 1 2 0 0 1 0 7 
Dyspepsia/gastric 
reflux 1 0 1 0 0 0 1 0 2 0 5 
Hypophosphataemia 1 0 1 0 0 3 0 0 0 0 5 
Pain 0 0 1 0 1 0 1 0 1 0 4 
Paronychia 0 0 3 0 0 0 1 0 1 0 5 
 
 
Table 1 
Toxicity in the dose escalation arm 
All drug related events (possibly, probably and, definitely related) seen in more than 20% of patients in the dose escalation 
cohorts.  
 
A total of 22 patients were treated in the dose escalation.  One patient was treated with vistusertib on schedule B at 50 mg 
instead of 100 mg due to urgent reporting of two dose-limiting toxicities.  The patient did not have grade 3 or 4 toxicity or a 
DLT, was evaluable, but has not been represented in the table for simplicity. 
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Variable Day 
AZD2014/Paclitaxel 
25 mg/80 mg 50 mg/80 mg 75 mg/80 mg 100 mg/80 mg 
Geometric Mean N Geometric Mean N Geometric Mean N Geometric Mean N 
AUClast (h*ng/mL) 3 2090 (1290-3462) 3 2602 (708-11486) 7 7543 (4192-16542) 9 7556 (4188-12884) 3 
8 1054 (181-2785) 3 2026 (800-6137) 7 5209 (1576-13363) 8 7347 (4875-13997) 3 
Cmax (ng/mL) 3 579 (478-785) 3 840 (462-3580) 7 1840 (983-2870) 9 1960 (1180-2670) 3 
8 248 (80-507) 3 500 (244-764) 7 1122 (442-1920) 8 1830 (1490-2420) 3 
HL Lambda_z (h) 3 3.3 (2.3-4.2) 3 1.8 (0.8-3.2) 6 2.7 (1.2-5.9) 8 3.0 (2.5-3.3) 3 
8 3.5 (1.9-6.1) 3 2.2 (1.7-2.9) 6 3.1 (1.7-9.7) 8 2.8 (1.2-5.3) 3 
 
 
 
 
Table 2.  Pharmacokinetic profile of vistusertib 
The area under the curve (AUC), maximal concentration (Cmax) and half-life (HL) of vistusertib on C1D3 (administered as a single agent)  
and C1D8 (administered in combination with paclitaxel) across the different dose levels in the dose escalation cohort. 
 



 Characteristics 
Total on Dose Escalation 
N (%) 
Total number of patients 22 
Primary tumour   
Ovary 8 (36) 
Lung adenocarcinoma 4 (18) 
Lung squamous 2 (9) 
Breast 1 (5) 
Endometrial 4 (18) 
Gastroesophageal 1 (5) 
Cervix 2 (9) 
 
 
   Supplementary Table 1.  Demographic profile of patients treated in the dose escalation cohort 
Characteristics Subtypes 
OVARIAN Expansion (50 mg 
AZD2014/80 mg Paclitaxel) 
LUNG Expansion (25 mg 
AZD2014/80 mg Paclitaxel) 
N (%) N (%) 
Primary tumour 
High grade serous ovarian 27 (100) - 
Lung squamous - 24 (100) 
Gender 
Male - 11 (46) 
Female 27 (100) 13 (54) 
Age (years) 
18 - 64 11 (41) 11 (44) 
≥65 16 (59) 13 (56) 
ECOG performance status 
0 7 (26) 4 (17) 
1 20 (74) 20 (83) 
Median previous lines of therapy   3 (range: 1 to 12) 2 (range: 1 to 3) 
Previously treated with taxane (incl. 
docetaxel or paclitaxel)   
26 (96) 
(Previous weekly taxol = 3) 6 (25) 
RECIST response    13 PR  8 PR (33) 
Median number of weeks on 
treatment   
21 18 
Ongoing on 1-Oct-2017   1 1 
Platinum sensitivity 
Platinum refractory 6 (22) 1 (4) 
Platinum resistance (< 6 months) 11 (41) 15 (63) 
Platinum intermediate sensitive (6 - 12 months) 9 (33) 4 (17) 
Platinum sensitive (> 12 months) 1 (4) 4 (17) 
 
Supplementary Table 2. Demographic profile of patients treated in the dose expansion cohort 
Lung Expansion 50 mg Vistusertib (N=17) 
 Adverse Event, N (%) Gr.1 - Gr.2 Gr.3 - Gr.4 Total % 
Fatigue 6 4 10 59 
Skin rash 8 1 9 53 
Anorexia/Appetite loss/Weight loss 8 0 8 47 
Diarrhoea 5 2 7 41 
Neuropathy 6 0 6 35 
Thrush (oral) 6 0 6 35 
Anaemia 4 1 5 29 
Bronchitis/Bronchial or respiratory 
infection 4 1 5 29 
Dyspnea/Shortness of breath 5 0 5 29 
Mucositis/Oral mucositis/Mouth ulcers 5 0 5 29 
Nausea 4 1 5 29 
Vomiting 5 0 5 29 
Pneumonitis/Pneumonia 3 1 4 24 
Cough 3 0 3 18 
Dry skin/Eczema 3 0 3 18 
Dyspepsia/Indigestion/GI tox 3 0 3 18 
Hyperglycaemia 2 1 3 18 
Leucopenia 2 1 3 18 
Neutropenia 2 1 3 18 
Aches and pain 2 0 2 12 
Alopecia 2 0 2 12 
Dry mouth 2 0 2 12 
Dysgeusia 2 0 2 12 
Elevated ALT 2 0 2 12 
Elevated AST 2 0 2 12 
Malaise/Sweats 2 0 2 12 
Paronychia/Nail changes 2 0 2 12 
Sore throat 2 0 2 12 
Cellulitis 0 1 1 6 
Drug reaction 1 0 1 6 
Epistaxis 1 0 1 6 
Glucose intolerance 1 0 1 6 
Headache 1 0 1 6 
Hyperbilirubinaemia 1 0 1 6 
Myalgia 1 0 1 6 
Red skin (face) 1 0 1 6 
Trigeminal nerve disorder 1 0 1 6 
UTI 0 1 1 6 
Total 110 16 126  
 
Supplementary Table 3A.  Toxicity profile of patients treated on the squamous 
non-small cell lung cancer expansion cohort 
Patients administered with 80 mg/m2 paclitaxel with 50 mg vistusertib bd 3/7 days for 6/7 weeks, 
dosing starting concurrently on day 1 of each week 
 
Lung Expansion 25 mg Vistusertib (N=24) 
Adverse Event, N (%) Gr.1 - Gr.2 Gr.3 - Gr.4 Total % 
Anaemia 14 0 14 58 
Fatigue 13 1 14 58 
Alopecia 13 0 13 54 
Neuropathy 11 0 11 46 
Nausea 10 0 10 42 
Bronchitis/Bronchial or Respiratory infection 4 4 8 33 
Diarrhoea 8 0 8 33 
Skin rash 7 0 7 29 
Dyspepsia/Indigestion 5 0 5 21 
Loss of appetite/Anorexia/Weight loss 4 1 5 21 
Mucositis/Mouth ulcers/Stomatitis 5 0 5 21 
Arthalgia/Myalgia 4 0 4 17 
Leucopenia 4 0 4 17 
Dry skin/Eczema 3 0 3 13 
Dyspnoea 3 0 3 13 
Lesion/Lump on skin 3 0 3 13 
Nail loss/discoloration 3 0 3 13 
Pneumonitis/Pneumonia 3 0 3 13 
Vomiting 3 0 3 13 
Abdominal cramps/pain 2 0 2 8 
Cough 2 0 2 8 
Elevated creatinine 2 0 2 8 
Epistaxis 2 0 2 8 
Hyperkalaemia 2 0 2 8 
Hypophosphataemia 1 1 2 8 
Leg oedema 1 1 2 8 
Neutropenia 1 1 2 8 
Tachycardia 2 0 2 8 
Coryzal symptoms 1 0 1 4 
Dehydration 0 1 1 4 
Dry mouth 1 0 1 4 
Early satiety 1 0 1 4 
Haemoptysis 1 0 1 4 
High magnesium 1 0 1 4 
High urea 1 0 1 4 
Hyponatraemia 0 1 1 4 
Hypotensive 0 1 1 4 
Increased glucose 1 0 1 4 
Long nails 1 0 1 4 
Low magnesium 1 0 1 4 
Naval discoloration 1 0 1 4 
Pruritis 1 0 1 4 
Thrush 1 0 1 4 
Wound breakdown 1 0 1 4 
Total 148 12 161  
 
Supplementary Table 3B. Toxicity profile of patients treated on the squamous 
non-small cell lung cancer expansion cohort 
Patients administered with 80 mg/m2 paclitaxel with 25 mg vistusertib bd 3/7 days for 6/7 weeks, 
dosing starting concurrently on day 1 of each week treated at paclitaxel 80 mg/m2/week and 
vistusertib 25 mg bd 3/7. 
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Supplementary data 
 
Inclusion and exclusion criteria 
Inclusion Criteria: 
1.  Histologically- or cytologically-proven solid tumour refractory to conventional 
treatment, or for which no conventional therapy exists or is declined by the 
patient, or where treatment with paclitaxel is an appropriate treatment option. 
Patients will be enrolled into two cohorts on the expansion phase. One cohort 
of the patients must have recurrent high grade serous ovarian cancer. 
Patients with clear cell ovarian are excluded. The other cohort of patients at 
expansion must have squamous cell lung cancer. 
2.  Patients who have had conventional treatment and where paclitaxel is 
appropriate. In instances where paclitaxel is appropriate but the patient has 
not already received it the patient may be enrolled after discussion between 
the referring oncologist and Principal Investigator. 
3.  Life expectancy of at least 12 weeks 
4.  ECOG performance status of 0-1 (Appendix 1) 
5.  Females should be using adequate contraceptive measures (see restrictions 
below), should not be breast-feeding and must have a negative pregnancy 
test prior to start of dosing if of child-bearing potential or must have evidence 
of non-child-bearing potential by fulfilling one of the following criteria at 
screening: 
Post-menopausal defined as aged more than 50 years and amenorrhoeic for 
at least 12 months following cessation of all exogenous hormonal treatments 
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Documentation of irreversible surgical sterilisation by hysterectomy, bilateral 
oophorectomy or bilateral salpingectomy but not tubal ligation 
6.  Male patients should be willing to use barrier contraception i.e., condoms 
7.  Measurable or evaluable disease. Patients enrolled in the expansion phase 
should have measurable disease by RECIST v1.1 criteria (Appendix 3). 
8.  Haematological and biochemical indices within the ranges shown below.  
These measurements must be performed within one week (Day -7 to Day 1) 
before the patient goes in the trial. 
 
 Laboratory Test Value required 
 Haemoglobin (Hb) ≥ 9.0 g/dL  
 Absolute neutrophil count ≥ 1.5 x 10 P9P/L  
 Platelet count ≥ 100 x 10P9P/L 
 Serum bilirubin  ≤ 1.5 x upper limit of normal (ULN)  
 Alanine aminotransferase (ALT) or 
aspartate aminotransferase (AST)   
≤ 2.5 x (ULN) if no demonstrable liver 
metastases or  ≤ 5 times ULN in the 
presence of liver metastases  
 Alkaline phosphatase (ALP) < 5 x ULN 
 Creatinine clearance 
OR  
Serum creatinine 
≥ 50 mL/min (uncorrected value) 
 
≤ 1.5 x ULN 
 Fasting glucose ≤ 125 mg/dL (7 mmol/L) 
 Erythrocyte-HbA1c  ≤ 59 mmol/mol 
 
9. 18 years or over 
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10. Written (signed and dated) informed consent and be capable of co-operating with 
treatment and follow-up 
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Exclusion criteria: 
1.  Radiotherapy (except for palliative reasons), chemotherapy, endocrine 
therapy, or immunotherapy during the previous 3 weeks (4 weeks for 
investigational medicinal products and 6 weeks for nitrosoureas and 
Mitomycin-C) before treatment.  
UN.B. Exceptions to this are patients receiving weekly Taxol as standard of 
care who have not had a partial or complete response after 6 to 12 weekly 
doses. Those patients should discontinue their weekly Taxol treatment and 
may be enrolled to the dose expansion phase without a wash out period. 
2.  Ongoing toxic manifestations of previous treatments. Exceptions to this are 
alopecia or certain Grade 1 toxicities, which in the opinion of the Investigator 
and the DDU should not exclude the patient. 
3.  Known leptomeningeal involvement, brain metastases or spinal cord 
compression 
4.  Known  hypersensitivity (>Grade 2) to taxanes, drugs containing Cremophor, 
AZD2014 or structurally/chemically similar drugs 
5.  Unresolved bowel obstruction 
6.  Current refractory nausea and vomiting, chronic gastrointestinal disease, 
inability to swallow formulated product or previous significant bowel resection 
that would preclude adequate absorption of AZD2014 
7.  Patients with Diabetes Type I or uncontrolled Type II (HbA1c >59 mmol/mol 
assessed locally) as judged by the investigator 
8.  Major surgery within 4 weeks prior to entry to the study (excluding placement 
of 
vascular access), or minor surgery within 2 weeks of entry into the study and 
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from which the patient has not yet recovered 
9.  Treatment with warfarin. Patients on warfarin for DVT/PE can be converted 
to LMWH. 
10.  Exposure to potent or moderate inhibitors or inducers of CYP3A4/5 if taken 
within the stated washout periods before the first dose of study treatment:  
• Inhibitors (competitive): ketoconazole, itraconazole, indinavir, saquinovir, 
nelfinavir, atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, 
fluconazole, nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine, P-
glycoprotein, grapefruit juice, or Seville oragnes (1 week minimum wash-out 
period), amiodarone (27 week minimum wash-out period) 
• Inhibitors (time dependent): erythromycin, clarithromycin, verapamil, 
ritonavir, diltiazem (2 week minimum wash-out period) 
• Inducers: phenytoin, rifampicin, St. John's Wort, carbamazepine, 
primidone, griseofulvin, carbamazepine, barbiturates, troglitazone, 
pioglitazone, oxcarbazepine, nevirapine, efavirenz, rifabutin (3 week 
minimum wash-out period) and phenobarbitone (5 week minimum 
washout period) 
11.  Exposure to potent or moderate inhibitors or inducers of CYP2C8 if taken 
within the stated washout periods before the first dose of study treatment: 
• Inhibitors: Gemfibrozil, trimethoprim, glitazones, montelukast, quercetin (1 
week minimum wash-out period) 
• Inducers: Rifampicin (3 week minimum wash-out period) 
12.  At high medical risk because of non-malignant systemic disease including 
active uncontrolled infection e.g. interstitial lung disease, severe hepatic 
impairment, uncontrolled chronic renal disease 
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13.  Known to be serologically positive for hepatitis B, hepatitis C or human 
immunodeficiency virus (HIV). 
14.  Patients who have experienced any of the following procedures or conditions 
currently or in the preceding 12 months: 
• coronary artery bypass graft 
• angioplasty 
• vascular stent 
• myocardial infarction (MI) 
• uncontrolled angina pectoris 
• congestive heart failure NYHA Grade 2 
• ventricular arrhythmias requiring continuous therapy 
• supraventricular arrhythmias including AF, which are uncontrolled 
• Torsades de Pointes 
• haemorrhagic or thrombotic stroke, including transient ischaemic attacks 
or any 
• other central nervous system bleeding 
15.  Resting ECG with measurable QTc interval of >470ms msec at 2 or more 
time points within a 24 hour period. 
16.  Concomitant medications known to prolong QT interval, or with factors that 
increase the risk of QTc prolongation or risk of arrhythmic events (such as 
heart failure, hypokalaemia, congenital long QT syndrome, family history of 
long QT syndrome), or unexplained sudden death under 40 years of age. 
Inability to discontinue medication with agents designated as having a risk of 
Torsades de Pointes due to QT prolongation (see Appendix 5) 
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17.  Left ventricular (LV) dysfunction (LVEF outside institutional range of normal) 
by MUGA or echocardiogram. 
18.  Current malignancies of other types, with the exception of adequately treated 
cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous 
cell carcinoma of the skin.  Cancer survivors, who have undergone 
potentially curative therapy for a prior malignancy who have no evidence of 
that disease currently are eligible for the trial. 
19.  Prior bone marrow transplant or have had extensive radiotherapy to greater 
than 25% of bone marrow within eight weeks of starting trial 
20.  Patients participating in or planning to participate in another interventional 
clinical trial whilst on this study. Participation in an observational trial is 
acceptable. 
21.  Any other condition which in the Investigator’s opinion would not make the 
patient a good candidate for the clinical trial. 
 
 
Prohibited concomitant medications 
UPotent and moderate inhibitors and inducers of CYP3A4/5 if taken within the stated 
Uwashout periodsU: 
Inhibitors (competitive): ketoconazole, itraconazole, indinavir, saquinovir, nelfinavir, 
atazanavir, amprenavir, fosamprenavir, troleandomycin, telithromycin, fluconazole, 
nefazodone, cimetidine, aprepitant, miconazole, fluvoxamine (1 week minimum 
wash-out period), amiodarone (27 week minimum wash-out period) 
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Inhibitors (time dependent): erythromycin, clarithromycin, verapamil, ritonavir, 
diltiazem (2 week minimum wash-out period) 
 
Inducers: phenytoin, rifampicin, St. John's Wort, carbamazepine, dexamethasone, 
primidone, griseofulvin, carbamazepine, barbiturates, troglitazone, pioglitazone, 
oxcarbazepine, nevirapine, efavirenz, rifabutin (3 week minimum wash-out period) 
and phenobarbitone (5 week minimum washout period) 
 
UPotent and moderate inhibitors and inducers of CYP2C8 if taken within the stated 
Uwashout periods: 
 
Inhibitors: Gemfibrozil, trimethoprim, glitazones, montelukast, quercetin (1 week 
minimum wash-out period) 
 
Inducers: Rifampicin (3 week minimum wash-out period) 
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Methods 
PK assay 
Outline 
This method is applicable to the analysis of AZD2014 in human plasma treated with 
K2EDTA anticoagulant. AZD2014 and the internal standard (ISTD), 
13C22H2AZ12729279 are extracted from human plasma by solid-phase extraction 
(SPE). After evaporation under nitrogen, the residue is reconstituted and analysed 
using liquid chromatography (LC) with tandem mass spectrometric detection (MS/MS). 
The standard curve range is from 20.0 to 20,000 ng/mL for AZD2014, using a plasma 
sample volume of 0.0250 mL. 
 
Solid phase extraction 
Condition the 96 Well Format SPE (Oasis HLB, 30 μm, 10 mg): Add 500 μL of 
methanol to the SPE cartridges and apply low pressure to let the solvent pass. Add 
500 μL of 10 mM ammonium formate in water to the SPE cartridges and apply low 
pressure to let the solvent pass. Load the entire 500 μL of the samples onto the SPE 
cartridges and apply very low pressure to let samples pass. Wash the SPE cartridges 
with 500 μL of 10 mM ammonium formate in water [MA1] and apply low pressure to 
let the solvent pass. Wash the SPE cartridges with 500 μL of 
methanol:water:ammonium hydroxide (30:65:5, v:v:v)  and apply low pressure to let 
the solvent pass. Dry the cartridges using maximum pressure for at least 20 seconds. 
Blot the tips dry on paper towelling. Place the cartridges on top of a clean pre-labelled 
Axygen 96-well plate. Add 300 μL of 2% formic acid in methanol to each SPE cartridge. 
Let the cartridges stand for 1 minute on top of the 96-well plate. Slowly elute the 
samples into the Axygen 96-well collection plate using minimal pressure. After 
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complete elution increase pressure to remove any remaining drips and dry the SPE 
packing material. Evaporate the extracts to dryness under a stream of nitrogen using 
the SPE Dry-96. Set the upper and lower gas temperature to 40°C. Set both upper 
and lower gas flow to approximately 50 L/min. The total evaporation time is 
approximately 20 minutes. Using an Eppendorf repeating pipette or Tomtec, 
reconstitute the samples by adding 500 μL of 10mM ammonium formate:methanol 
(3:2, v:v) [RC1] to each sample. Cover the 96-well plate with a dimpled sealing mat 
and vortex-mix at a low speed for approximately 1 minute. Perform a 20x dilution of 
each sample using a Tomtec. Transfer 25 μL of each sample from Step 5 to a clean 
pre-labeled Axygen 96-well plate. Dilute each sample by adding 475 μL of 10mM 
ammonium formate:methanol (3:2, v:v) [RC1]. Cover the 96-well plate with a dimpled 
sealing mat and vortex-mix at a low speed for approximately 1 minute. Keep sample 
extracts at refrigerated conditions if needed prior to injection. 
 
UChromatographic Conditions 
Column: Waters, Acquity UPLC® BEH C18, 2.1 x 50 mm, 1.7 μm particle size 
Pre-filter: Waters, Acquity column inline filter 
Column Temp.: 60°C 
Mobile Phase: A: 10 mM ammonium formate in water B: methanol 
Gradient Program: Initial Conditions: 0.600 mL/min; 50 % B 
 
Time 
(minutes)  Module   Function Value  (%) 
0.30   Pumps    Pump B Conc.   50 
2.00   Pumps    Pump B Conc.   75 
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2.10  Pumps    Pump B Conc.   98 
2.50   Pumps    Pump B Conc.   98 
2.60  Pumps    Pump B Conc.   50 
3.50  System Controller  Stop 
 
Flow Rate: 0.600 mL/min 
Back Pressure: 410 Bar (Typical) 
Sample Tray Temp: Refrigerated temperature (2 to 8°C) 
Injection Volume: 5-10 μL (Typical); Not to exceed 20.0 μL 
Rinse Port Injector 
Wash Solution: 10mM ammonium formate:methanol (3:2, v:v)  
Rinse Pump Injector 
Wash Solution: Methanol: DMSO (4:1, v:v)  
Needle Stroke: 47 mm 
Rinse Pump Setting: Rinse pump → Rinse port 
Rinse Volume: 500 μL 
Rinse Mode: Before and After Sampling 
Rinse Dip Time: 3 seconds 
Rinse Time: 1 second 
Acquisition Time: Approximately 3.5 minutes 
Cycle Time: Approximately 4.0 minutes (injection start to next injection start) 
Mass Spectrometer Parameters 
Mass Spectrometer: Sciex API 4000 
Ionization: Positive Ion Electrospray (ESI+) 
Mode: MRM 
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IonSpray Voltage: 4500V 
TurboIon Spray Temp: 600°C 
Curtain Gas Type: Nitrogen Setting: 30 
CAD Gas Type: Nitrogen Setting: 6 
Nebulizing Gas (Gas1) Type: Nitrogen Setting: 50 
Auxiliary Gas (Gas 2) Type: Nitrogen Setting: 70 
Needle Position: Y = 5 mm 
X = 5 mm 
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Pharmacodynamic biomarker analysis: peripheral blood mononuclear cells 
(PBMCS) and platelet rich plasma (PRP) 
Peripheral blood mononuclear cells (PBMCs) fixed with 4% formaldehyde were 
incubated for ten minutes with 4% fetal calf serum (FCS), 0.1% Triton X-100, PBS as 
a blocking agent followed by staining with excess anti-phospho 4EBP1 (Thr37/46) 
(236B4) Rabbit monoclonal antibody Alexa 488 conjugate (2846, Cell Signaling 
Technology, Massachusetts, USA). Stained samples were washed once in 4% FCS, 
0.1% Triton X-100, PBS and once in 0.1% Triton X-100, PBS. Stained samples were 
suspended in an appropriate volume of 0.1% Triton X-100, PBS and analysed using 
a FACSCantoII. A rabbit IgG isotype control (4340, Cell Signaling Technology, 
Massachusetts, USA) was used to set the negative population and assess the 
percentage of monocytes positive for phosphorylated 4EBP1. During validation the 
inter-assay precision, ranged from 2.8 to 3.3%. 
 
pAkt was assessed in platelet rich plasma (PRP) using a sandwich immunoassay as 
per manufacturer’s instructions (K11100D, Meso Scale Discovery, Maryland, USA) 
which consisted of a multiplex assay with  plates pre-coated with phospho(Ser473) 
Akt and total Akt capture antibodies. These plates were blocked for 1 hour, incubated 
with sample for 1 hour, and finally incubated with an anti-total Akt detection antibody 
conjugated to MSD-SULFO-TAG for 1 hour before being detected on a Meso Scale 
Discovery Sector Imager 6000 using electrochemiluminescence in order to determine 
the percentage of Akt phosphorylated. During validation the inter-assay precision 
ranged from 6.75 to 7.17%. 
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Inter-assay precision for both methods was determined as the co-efficient of variance 
(CV) of 3 independent measurements across 3 days.  
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Genomic Sequencing  
 
DNA was extracted from formalin-fixed and paraffin-embedded (FFPE) tumour blocks 
using the FFPE Tissue DNA kit (Qiagen). DNA was quantified with the Quant-iT high-
sensitivity PicoGreen double-stranded DNA Assay Kit (Invitrogen). Sequencing 
libraries were constructed from 40 ng of DNA using a customized Generead DNAseq 
Mix-n-Match v2 panel (Qiagen) covering 4841 amplicons (310,077 bp) across 67 
genes.  Libraries were run using the MiSeq Sequencer (Illumina) at a mean of 650X 
(tissue) and 1018X (cfDNA).  FASTQ files were generated using the Illumina MiSeq 
Reporter v2.5.1.3. Sequence alignment and mutation calling were performed using 
BWA tools and the GATK variant annotator by the Qiagen GeneRead Targeted Exon 
Enrichment Panel Data Analysis Web Portal.  In addition, circulating free DNA (cfDNA) 
when collected at baseline, at the end of cycle 1 and, where possible, at progression, 
was extracted from 4 - 8 mL of plasma using the QIAsymphony (Qiagen) and the 
Circulating DNA Kit (Qiagen) and quantified by Quant-iT High Sensitivity Picogreen 
Kit (Invitrogen).  
 
 
